XCath, a Houston-based medical technology firm, has successfully secured $30 million in a Series C financing round. The investment was co-led by Crescent Enterprises and Dr. Fred Moll, a renowned pioneer often called "the father of surgical robotics." This latest capital injection brings the company's total funding since its inception to an impressive $92 million, fueling its mission to commercialize its innovative robotic technology.
Advancing Endovascular Robotics
The new funds are earmarked to advance XCath's groundbreaking Iris endovascular robotic system toward market readiness. This platform is designed to facilitate clinical telerobotic mechanical thrombectomy procedures for patients suffering from neurovascular diseases. The technology aims to significantly improve outcomes for complex conditions such as strokes and brain aneurysms by enhancing procedural precision and control.
XCath recently achieved a critical milestone with the first-in-human application of its Iris robotic system. The company reported the successful use of the platform to treat three patients diagnosed with complex brain aneurysms. This achievement marks only the second time in history that a surgical robot has been utilized for an intracranial neurovascular intervention, signaling a major leap forward.
A Landmark in Surgical Innovation
The Iris system stands out as the only endovascular robotic platform currently in development capable of achieving intracranial navigation for neurointerventional treatment. It is also distinguished as the sole robot globally to perform such a procedure by manipulating three separate devices. Furthermore, the system operates effectively using standard monoplane imaging equipment, enhancing its accessibility for hospitals.
Eduardo Fonseca, CEO of XCath, expressed gratitude for the investors' belief in the company's mission to improve patient outcomes. He stated that this funding accelerates their commitment to expanding access to life-saving care for endovascular diseases. Fonseca emphasized the goal of ensuring that a patient's location no longer dictates their chances of survival and recovery.
Investor Confidence and Market Opportunity
The involvement of Dr. Fred Moll as a co-lead investor and board chair lends significant credibility to XCath's approach. Dr. Moll noted that robotic surgery succeeds when innovation is paired with practical execution, praising the company's promising technology and rigorous team. He expressed his excitement in supporting their mission to globalize access to premier care for stroke patients.
Neeraj Agrawal, an XCath board member and executive director at Crescent Enterprises, echoed this confidence from an investment perspective. He identified surgical robotics as one of the most compelling long-term opportunities in the healthcare sector. Agrawal commended XCath for assembling an exceptional team focused on addressing a significant global unmet medical need.
The global neurovascular device market is projected to exceed $4 billion by 2027, driven by rising disease prevalence and demand for minimally invasive options. XCath CFO Nicholas Drysdale highlighted that treating stroke represents a major financial opportunity supported by positive reimbursement dynamics. This positions the company to build a category-leading platform with its disciplined capital deployment and strong investor support.
This $30 million Series C funding round marks a pivotal moment for XCath, solidifying its path toward commercializing its advanced robotic system. The investment not only validates the company's technological progress but also equips it to address a critical need in neurovascular care. With this support, XCath is poised to transform the treatment landscape for stroke and other complex conditions, making high-quality care more accessible worldwide.